Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (5.7), the stock would be worth ¥12.04 (8% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.2 | ¥11.1 |
0%
|
| 3-Year Average | 5.7 | ¥12.04 |
+8%
|
| 5-Year Average | 5.9 | ¥12.56 |
+13%
|
| Industry Average | 25 | ¥53.2 |
+379%
|
| Country Average | 18.3 | ¥38.84 |
+250%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
J
|
Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380
|
20.3B CNY | 5.2 | 15.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 47.8 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 22.3 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 19.5 | 27.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 14.5 | 20.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 16.7 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 12.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 8.2 | 16.4 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Joincare Pharmaceutical Group Industry Co Ltd
Glance View
Joincare Pharmaceutical Group Industry Co. Ltd., a noteworthy player in China's bustling pharmaceutical landscape, emerged as a beacon of innovation and resilience. With its roots stretching back to the mid-1990s, the company has consistently carved out a substantial niche in both the generic and proprietary drug markets. Its ability to synergistically blend cutting-edge research with cost-efficient production has been instrumental in ensuring its position as a formidable competitor. Joincare harnesses a robust pipeline of drugs targeting prevalent chronic diseases, complemented by its investment in high-growth biopharmaceuticals. From research and development to manufacturing and distribution, Joincare manages an integrated pharmaceutical supply chain that not only propels its profitability but also reinforces its mission to enhance public health. The company thrives on a diverse revenue model by leveraging both its proprietary products and a broad array of generic pharmaceuticals. It capitalizes on sustained demand for its products across domestic and international markets, ensuring a steady stream of income. By focusing on quality and affordability, Joincare has successfully navigated the complex regulatory landscape, earning certifications that open doors to global markets. This strategic emphasis on rigorous compliance not only mitigates risks but also builds trust with healthcare professionals and end-users alike. Through these efforts, Joincare continues to fortify its market position, all while contributing to the ever-evolving pharmaceutical industry with a pioneering spirit and an unwavering commitment to improving healthcare accessibility.